Enterprise Value

79.51M

Cash

268.7M

Avg Qtr Burn

-71.4M

Short % of Float

27.36%

Insider Ownership

3.09%

Institutional Own.

-

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

ZORYVE® (ARQ-151) topical roflumilast cream (PDE4 Inhibitor) Details
Psoriasis, Skin disease/disorder, Chronic obstructive pulmonary disease, Pulmonary hypertension

Approved

Quarterly sales

PDUFA

Approval decision

Roflumilast foam 0.3% Details
Skin disease/disorder, Seborrheic dermatitis

Big Mover™

Susp. Mover™

PDUFA

Approval decision

sNDA

Submission

sNDA

Submission

ARQ-255 topical ivarmacitinib (JAK1 inhibitor) Details
Skin disease/disorder, Alopecia areata

Phase 1b

Data readout

ARQ-252 (JAK1i) Details
Skin disease/disorder, Eczema

Failed

Discontinued

Failed

Discontinued